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Abstract

Obesity and overweight arise due to an abnormal fat accumulation in the body that presents a
risk to health. Individuals with body mass index (BMI) of greater than 30 kg/m2 are considered
obese. CDC data show that 43% of the adults in the US are obese. The prevalence of obesity as
well as its strong association with cardiovascular and metabolic diseases are the serious concerns
of public health which calls for the need of appropriate diet/nutrition that can minimize the
negative effect of obesity.

Literature suggests that 50% of the contribution to obesity can be attributed to genetics.
However, studies are mostly focused on the association between mother’s obesity (maternal) and
child’s health only. Father’s obesity (paternal) although equally important, has been scarcely
studied. In my research, we focused on the effect of paternal obesity on child’s health, and
experimentally investigated effects of fish oil (FO) on the obese father that can mitigate risk of
obesity and associated diseases on children. Due to several metabolic benefits of FO, we
hypothesized that the FO supplementation to an obese father during the pre-conception period
could improve metabolic health of the offspring.

Three groups of male mice were fed low fat (LF), high fat (HF) or high fat supplemented diet
with FO for 10 weeks and then allowed to mate with female mice (all female mice fed with LF
only). After the offspring were born, birth weight was recorded weekly. Glucose and insulin
tolerance were performed in the offspring at 12 weeks of age. Offspring were sacrificed at 16
weeks of age to collect muscle, liver, and adipose tissue. To comprehend the short-term and

long-term effect of the paternal obesity and FO intervention, we investigated offspring sacrificed
at 8 weeks of age (short-term) and at 16 weeks of age (long-term).

It was observed that the offspring of HF fed fathers were obese, while offspring of FO fed fathers
were metabolically healthier during their later stage of life. Glucose and insulin tolerances of
offspring of FO fed fathers were significantly improved as compared to offspring of HF fed
fathers.

Hematoxylin and eosin staining revealed higher deposition of fat in the liver of offspring of HF
fed fathers, which was not evident in the offspring of FO fed fathers.

Gene expression analyses indicated significantly higher expression of pro-inflammatory
biomarkers (IL6, TNF-a, PDK4, SREBP-1c) in the liver of offspring of HF fed fathers as
compared to that of offspring of LF fed fathers (n = 8-10, p < 0.05). Further these markers were
lower significantly in offspring of FO supplemented father. Similar findings were obtained in the
case of the fatty acid synthesis biomarker (FASN) where expression in liver was significantly
higher in offspring of HF fed father as compared to offspring of LF fed fathers. This was
subsequently minimized due to FO supplementation in obese father. The analysis of fatty acid
oxidation biomarkers showed an interesting outcome with higher expression of FOXO and CPT1 in liver of offspring of FO fed fathers as compared to that on offspring of HF fed fathers at 8
weeks of age. This differentiation later was diminished with no significant difference observed at
16 weeks of age. Overall, the expression of biomarkers highlighted the role of FO
supplementation on paternal obesity to eliminate the risk of metabolic and cardiovascular

diseases in offspring. Further probe is necessary to understand the expression and metabolism of
fatty acid oxidation biomarkers in paternal obesity.

The present study summarizes that FO supplementation in fathers shows potential to reduce
metabolic and cardiovascular diseases in children.
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Chapter 1. INTRODUCTION TO OBESITY

1.1 Definition

Obesity, is traditionally defined as “having body weight at least 20% above the ideal
recommendation for individuals of a specific height, gender and age” [1]. According to the
World Health Organization (WHO), overweight and obesity is defined as abnormal or
excessive fat accumulation that presents a risk to health and is quantified by a simple metric
of body mass index (BMI) [2]. BMI is calculated as a ratio of body weight in kilograms to the
square of height in meters. According to the current guidelines from the US Centre for
Disease Control and Prevention (CDC) and the WHO, healthy BMI ranges from 18.5 to 24.9,
whereas a BMI ≥ 25 kg/m2 is considered to be overweight, BMI ≥ 30 kg/m2 is obese and a
BMI ≥ 40 kg/m2 is classified as severe obesity. Obesity is subdivided into three different
categories; Class 1 with BMI of 30 to 35, Class 2 with BMI of 35 to 40 and Class 3 with BMI
of 40 or more, categorized as ‘extreme’ or ‘severe’ obesity.

1.2 Etiology of Obesity

Obesity is a multi-faceted chronic disease resulting from long-term positive energy balance
with the development of excess adiposity. It is caused by the interaction of multiple genetic,
metabolism, environmental and behavioral factors [3]. Moreover, 50% of the variation in
body weight can be ascribed to genetic factors [4]. Jastreboff et al. revealed that obesity
might lead to abnormalities in body structure, physiological derangements and functional
impairments [5]. Like other chronic diseases, it has been distinguished by diverse
phenotypes, physical examinations and treatments. Hence, it has become a public health
burden with remarkable and profound impact on morbidity, mortality and health care costs
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[3]. Increase in body weight is frequently associated with several metabolic complications
like insulin resistance, impaired glucose tolerance and dyslipidemia that are important risk
factors for the development of type-2 diabetes (T2D) and cardiovascular diseases (CVD) [6].
Non-communicable diseases (NCDs), including CVD, cancer and T2D, account for >70% of
early deaths worldwide, hence representing a leading cause of mortality and premature
disability [6].

1.3 Prevalence in the World and the US

According to WHO (2016), there are around 2 billion adults who are overweight, out of those
650 million are affected by obesity (BMI > 30kg/m2). That equates to 39% (39% of men and
40% of women) of adults aged 18 or over who were overweight, with 13% obese. The
worldwide prevalence of obesity tripled in 2016 as compared to 1975. Globally, more than
1.9 billion adults were overweight and 650 million were obese in 2019. Approximately 2.8
million deaths are reported as a result of being overweight or obese [7]. If the incidence
continues at this rate, almost half of the world’s adult population will be overweight or obese
by 2030. Further, obesity prevalence is estimated to be 15-20% (often 10-15% in men and
15-20% in women) within the age group of 25 to 55 years [8]. In the USA, obesity is more
prevalent with even higher numbers in certain subgroups such as non-whites. The prevalence
is lower in sub-Saharan Africa and Asia where the majority of the world population lives.

Within the topic of obesity, childhood or adolescent obesity is one of the most important
issues in global health. About 40 million children under the age of 5 years and more than 330
million children and adolescents aged 5-19 years were overweight or obese in 2016 in US [9].
Given the global emergency posed by childhood and adolescent obesity, WHO endorsed “no
increase in childhood overweight by 2025” as one of the six global nutrition targets in the
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CIP-MIYCN (Comprehensive Implementation Plan for Maternal, Infant and Young Child
Nutrition). Globally, the prevalence of overweight rose modestly, from 4.8% in 1990 to 5.9%
in 2019, but with estimates for low and middle-income United Nations regions showing
heterogeneous trend [9].

1.3.1 Prevalence of Obesity by Age-group:

Prevalence of Obesity
48

46.4
46

44.8

Percent

44

42.8

42.4

43.3

43
42.2

42

40

40

41.9

40.3

43.3

39.7

38
36
Total

Men
20 and over

Women

20-39

40-59

60 and over

Figure 1.1. Prevalence of Obesity among adults aged 20 and over, by sex and age: United
States, 2017-2018 Source: NCHS, National Health and Nutrition Examination Survey, 20172018 [10].

The distribution of obesity prevalence among different age groups in adult in the US is
illustrated in Fig. 1. Of the total adult men and women in the US, 42.4 % suffer from obesity
as per the data of 2017-2018. Also, the age group of 40-59 years has maximum obesity
prevalence. The chart also elucidates differences in obesity prevalence among men and
women. As compared to women, the prevalence of obese men is higher.
3

1.3.2 Prevalence of obesity by geographical locations:

Table 1.1 US State Obesity Levels and Rankings, 2018 & 1990 Source: State of Obesity,
“Obesity Rates: Adults,” Sep. 2019

2018
Rank

% of
population
STATE
that was obese
in 2018

% change
from 1990
to 2018

% of population
that was obese in
1990

1990
Rank

11.1
39.6*

Average

182.0
(44 states & DC)

1

39.5

Mississippi

163.3

15.0

1

1

39.5

West Virginia

188.3

13.7

4

3

37.1

Arkansas

n/a

n/a

n/a

4

36.8

Louisiana

199.2

12.3

10

5

36.6

Kentucky

188.2

12.7

9

6

36.2

Alabama

223.2

11.2

21

7

35.3

Iowa

189.3

12.2

11

8

35.1

North Dakota

202.6

11.6

15

9

35.0

Missouri

209.7

11.3

17

10

34.8

Oklahoma

237.9

10.3

31

10

34.8

Texas

225.2

10.7

26

12

34.4

Kansas

n/a

n/a

n/a

4

12

34.4

Tennessee

209.9

11.1

23

14

34.3

South Carolina

185.8

12.0

13

15

34.1

Indiana

156.4

13.3

6

15

34.1

Nebraska

201.8

11.3

17

17

34.0

Ohio

200.9

11.3

17

18

33.5

Delaware

132.6

14.4

2

19

33.0

Michigan

150.0

13.2

8

19

33.0

North Carolina

148.1

13.3

6

21

32.5

Georgia

221.8

10.1

33

22

32.3

New Mexico

298.8

8.1

44

23

32.0

Wisconsin

171.2

11.8

14

24

31.8

Illinois

162.8

12.1

12

25

30.9

Maryland

186.1

10.8

25

25

30.9

Pennsylvania

125.5

13.7

4

27

30.7

Florida

169.3

11.4

16

28

30.4

Maine

178.9

10.9

24

28

30.4

Virginia

169.0

11.3

17

30

30.1

Minnesota

192.2

10.3

31

30

30.1

South Dakota

181.3

10.7

26

32

29.9

Oregon

167.0

11.2

21

5

33

29.6

New Hampshire

199.0

9.9

37

34

29.5

Alaska

n/a

n/a

n/a

34

29.5

Arizona

178.3

10.6

29

34

29.5

Nevada

n/a

n/a

n/a

37

29.0

Wyoming

n/a

n/a

n/a

38

28.7

Washington

184.2

10.1

33

39

28.4

Idaho

205.4

9.3

3

40

27.8

Utah

208.9

9.0

41

41

27.7

Rhode Island

174.3

10.1

33

42

27.6

New York

196.8

9.3

39

43

27.5

Vermont

157.0

10.7

26

44

27.4

Connecticut

163.5

10.4

30

45

26.9

Montana

220.2

8.4

43

46

25.8

California

160.6

9.9

37

47

25.7

Massachusetts

154.5

10.1

33

47

25.7

New Jersey

n/a

n/a

n/a

49

24.9

Hawaii

179.8

8.9

42

50

24.7

DC

71.5

14.4

2

51

23.0

Colorado

233.3

6.9

45
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A report of the State of Obesity provides a comprehensive data about the prevalence of
obesity in 50 states and the D.C since 1990 to 2018. It also provides the change in the obesity
prevalence in past 3 decades in each state as shown in Table 1.1.

1.4 FACTORS AFFECTING OBESITY

Several factors including diet, genetics, hormones, physical activities, etc. are responsible for
affecting obesity in adult. Each one of the factors are discussed in detail as follows:

1.4.1 Diet

Dietary fat is claimed to be responsible for an increase in obesity. Experimental study in
animal model has shown that high-fat diets (>30% of energy from fat) can easily induce
obesity [11]. Research conducted in countries like China, Canada and the USA have
confirmed that incidence of obesity increases in proportion with the average amount of fat in
diet. This has led to global effort to reduce the amount of fat in human diet. As early as 1949,
obesity was studied in rats by feeding a semi-liquid diet. Later in 1953, high-fat diets with fat
at 50% of total energy was used in weanling mice to induce diet induced obesity [11]. Since
under-reporting is an important bias in epidemiological studies on diet and obesity in human
subjects, animal models have been widely utilized for experiments on dietary obesity.
Generally, high-fat diets within the range of 30-78 % of total energy intake are used either by
adding a particular fat to the animal’s diet or by using a variety of fat and high-sugar
supermarket foods for studying obesity in rats and mice.

1.4.2 Genetics
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Genes play a significant role in the regulation of body weight, size, overall composition, and
metabolic responses to feeding in humans. Different studies show the implication of maternal
and paternal obesity on offspring body development and adiposity [12, 13]. Also, crucial
metabolic activities that regulate glucose levels and insulin resistance are found to be altered
as a result of maternal obesity, programmed through genes. The genetic contribution to
obesity has been established through various studies, with one study reporting heritability of
40 to 70% which is only slightly less than that for height [14].

1.4.3 Geography

Obesity prevalence is also influenced by geographical location. Around 55% of global
increases in BMI can be ascribed to rising BMI in rural areas. Rural areas are associated with
1.36 higher odds ratio of obesity (or 36% more susceptible) in comparison to urban areas.
Rural areas have longer distances between residences and supermarkets, hospitals and
educational institutes which can influence the ability to practice healthy behaviors that
prevent obesity [15]. Another indirect effect of geographical differences is in terms of food
availability. Increasing body weight is linked with availability of food. People purchase and
eat whatever food is available near them. Food availability includes type of foods, quality,
amount, and pricing influences eating habits of people and body weight. A study suggested
that fast food restaurant density is associated with obesity prevalence [15].

1.4.4 Hormones

Hormones like insulin, leptin, estrogen and androgen affects our body metabolism and fat
distribution. Likewise, obesity pathophysiology and the resultant obesity-related disease risks
differ in women and men. Pre-clinical and clinical research indicate that ovarian hormones
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play a major role in women body weight of reproductive-age groups In line with this, severe
obesity is more prevalent in women compared to men [12].

1.4.5 Stress

Stress is associated with obesity, and the neurobiology of stress overlaps significantly with
that of appetite and energy regulation. Chronic stress can lead to overeating foods that are
high in fat, sugar, and calories, resulting in weight gain. Stress causes anxiety which causes
fat to build up in the stomach, increasing the risk of obesity [16].

1.4.6 Work environment and advances in communication technology

Our physical activity depends on our work environment, as we spend enormous time in the
workplace. From 1960 to 2010, jobs in the U.S. private industry shifted from 50% requiring
at least moderate to vigorous physical activity to less than 20% requiring higher intensity of
physical activity [15]. New communication technology including screen time has also been
found to be associated with increased risk for obesity. Ironically, researchers are now using
that same technology to help with obesity prevention and treatment.

1.4.7 Physical Activity

Weight status is directly associated with physical activities like exercise, walking or
bicycling. Physical activity together with the mode of transportation people prefer is directly
associated with body weight and thus the state of obesity. Higher walkability rate has been
found to be associated with decreased prevalence of overweight and obesity. A study shows
that the transport-related physical activity decreased by 17.8% between 1965 and 2009 in US
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due to advancements in transportation technology and our busy work schedules, which is also
a key factor affecting the prevalence of obesity in the US [15].

1.4.8 Educational level

Table 1.2: Prevalence of obesity according to education levels. Source: CDC, Behavioral risk
factor surveillance system, 1991–2001

Obesity Prevalence (%)
Education level
1991

1998

2000

2001

Less than high school

16.5

24.1

26.1

27.4

High school

13.3

19.4

21.7

23.2

Some college

10.6

17.8

19.5

21.0

College

8.0

13.1

15.2

15.7

As shown in the table above, the distribution of obesity prevalence among the people of
different education level is quite significant. It provides a clear indication that those who are not
formally educated tend to have lesser awareness about healthy diet which leads to a higher rate
of obesity [17].
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1.5 Implications of obesity

Obesity imposes a large economic burden on the individual, families and nations as it is strongly
associated with serious medical complications (e.g., type-2 diabetes, hypertension, dyslipidemia,
coronary heart disease, stroke, gallbladder disease, osteoarthritis, mental illness, respiratory
disease, many types of cancer, musculoskeletal and liver diseases) [18] . Thus, obesity is
considered to have a greater impact on global health, economy, and psychosocial aspects which
are explained below.

1.5.1 Economic implications

In 2014, global economic impact of obesity was estimated to be US $ 2.0 trillion or 2.8% of the
global gross domestic product (GDP) [19]. Besides health care expenditures, it is also
associated with lost workdays, lower productivity at work, mortality and disability. In 2011, the
health care costs associated with obesity in the US was estimated close to $150 billion [20].

1.5.2 Psychosocial implications

Being overweight has a tremendous impact on the social and psychological functioning of
individuals and families, because of the chronicity of this illness. Obesity is also linked with less
schooling, poorer work habits, lower income, emotional and interpersonal problems.
Additionally, obesity causes poor self-image, low self-esteem and social isolation, that all
contributes to depression [21].

1.5.3 Health implications
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Figure 1.2 Pathogenesis of Health Problems associated with Obesity (adopted from [22]).

CVD: Cardio-vascular diseases NAFLD: Non-alcoholic fatty liver diseases

GB: Gall bladder diseases

i.

Insulin resistance

Obesity is related with an increased risk of developing insulin resistance. Adipose tissue (AT)
in obese individuals secrete higher amounts of non-esterified fatty acids, hormones, glycerol
and other factors, all of which contribute to development of insulin resistance. Insulin
resistance is manifested by decreased insulin-stimulated glucose transport, impaired hepatic
glucose output and dysregulated metabolism in adipocytes and skeletal muscle. This can
result from impaired insulin signaling in adipocytes, also from down regulation of the major
insulin-responsive glucose transporter GLUT4 [23].
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ii.

Sleep apnea

A study has suggested that the increased neck circumference and fat deposits in the upper
respiratory tract pharyngeal area may lead to the obstructive sleep apnea in people with
obesity [22]. Losing at least 10% of body weight can have a big effect on sleep apnea
symptoms. The prevalence of obstructive sleep apnea (OSA) rises remarkably with increasing
adiposity. A study has declared that 50-70% of obese and overweight subjects suffering OSA
[24].

iii.

Diseases of bones, joints, and skin

Increase in the prevalence of osteoarthritis is directly associated with obesity [22]. Gaining
weight puts more pressure on knees. Excess weight has a greater risk of infections, stretch
marks, melanoma, inflammation, poor wound healing, etc. Acanthosis nigricans with
deepening pigmentation in the folds of the neck, knuckles and extensor surfaces [25] along
with insulin resistance is found to be associated with obesity [26].

iv.

Diabetes mellitus

The increasing global prevalence of type 2 diabetes mellitus (T2DM) is linked to rising rates
of obesity – as a consequence of social trends toward higher energy intake and reduced
energy expenditure [27]. T2DM is strongly correlated with obesity in both sexes. The risk of
T2DM expands with the degree and duration of overweight and with a more central
distribution of body fat. Up to 65% of T2DM cases are attributed to excess body weight. Of
the 11.7 million cases of diabetes, obesity accounts for two-third of diabetic deaths [22].
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v.

NAFLD

A range of liver conditions affecting people who drink little to no alcohol is called NAFLD,
which is associated with obesity, including hepatomegaly, elevated liver enzymes and
abnormal liver histology such as steatosis, fibrosis and cirrhosis. A retrospective analysis of
liver biopsy specimens obtained from overweight and obese patients revealed 30%
prevalence of septal fibrosis and 10% prevalence of cirrhosis [22].

vi.

Gall Bladder diseases

Cholelithiasis is the main hepatobiliary pathology related to obesity. The old clinical axiom
“fat, female, fertile and forty” explains the epidemiological factors connected with the
development of GB disease. Cholesterol production is linearly associated to body fat, around
20 mg of additional cholesterol are synthesized for each kilogram of extra body fat.
Consequently, a 10 kg increase in body fat leads to the daily synthesis of total cholesterol
contained in one egg yolk [22]. High cholesterol concentrations relative to bile acids and
phospholipids in bile increases the possibility of precipitation of cholesterol gallstones in the
gallbladder.

vii.

Hypertension and CVD

Obesity and high blood pressure are the crucial components of the cardio-metabolic
syndrome [28]. Both are on the rise worldwide with expansive consequences on global health
and global economy. The connection between hypertension and obesity is vague; the etiology
is complex and not clarified.
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If a person is overweight or obese, his heart has to make extra effort on arteries to pump
blood throughout body. Arteries, in turn, withstand the flow of blood, causing blood pressure
to rise [22]. Obesity is a multifactorial trait that comprises an independent risk factor for
CVDs [29]. Data from the Nurses’ health study shows that the risk for US women developing
coronary artery disease is increased by 3.3 fold with a BMI > 29kg/m2 compared with that in
women with a BMI < 21kg/m2. A BMI of 27 to less than 29 kg/m2 increases the relative risk
to 1.8 [22].

viii.

Cancer

Excess body fat increases the risk of several cancers; males face increased risk for neoplasms
of the colon, rectum and prostate, whilst gallbladder cancer and cancers of reproductive
system are more common in females [22]. The increased risk of endometrial cancer in
overweight females is the increased production of estrogen by AT stromal cells. This
increased production is associated with obesity that accounts for the major source of estrogen
production in post-menopausal females [22].

In postmenopausal women, obesity increases the risk of breast cancer due to estrogen levels
[30]. Even so, before menopause, increased body weight is contrarily related to breast cancer
risk. In both premenopausal and postmenopausal breast cancer, the mechanisms by which
body weight and obesity affect risk is dependent on estrogenic activity.
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Chapter 2. OBESITY AND FATTY LIVER

2.1 Liver inflammation and Cirrhosis

Fatty liver is the term used when there is excess fat in the liver which cannot be credited to
known causes of liver diseases such as alcohol, viruses, drugs or toxins. Around 70% of
elevated liver enzymes are due to non-alcoholic fatty liver diseases (NAFLD) [31] [32]. This
results in wide varieties of liver abnormalities including hepatic steatosis with or without
mild increases in serum AST/ALT to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis,
and incidental hepatocellular carcinoma [33]. The spectrum of NAFLD ranges from hepatic
steatosis to cirrhosis. 23 to 24% of the adults in the US are estimated to have NAFLD and
2.5% of the adults have NASH. Also, if we look into the trends of obesity among women
aged 20-39 years in the US, the prevalence of the same is rising at the rate of 29%. Thus it is
important to look into the combined data of obesity and NAFLD/NASH, because studies also
suggest positive correlation of the prevalence rate of NAFLD with BMI [34]. Cirrhosis, is a
complication in which healthy liver tissue is replaced by scar tissue. The cause of cirrhosis is
identified by the patient’s history combined with serological and histological investigation.
Cirrhosis is an increasing cause of morbidity and mortality, specifically in developed
countries [35]. It is the 14th most common cause of death worldwide whilst 4th in central
Europe. It results in 1.03 million deaths per year worldwide, 170,000 per year in Europe and
33,539 per year in US. Moreover, with the increasing prevalence of obesity, NAFLD has
become a serious medical problem in many developed as well as developing countries.

2.2 Effect of obesity on inducing fatty liver
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Obesity is the one of the main risk factors for NAFLD and the more severe non-alcoholic
NASH. NASH is caused by fatty liver inflammation, which is believed to cause fibrosis and
cirrhosis, the detail process is also explained later in this section. Liver fat is however, closely
related to insulin resistance. This holds for both sexes, even though women in general have
more subcutaneous and less visceral fat than men [31].
A study suggests that the rising rates of obesity and obesity-induced liver disease i.e. NAFLD
is due to availability of cheap energy dense foods and the effects of maternal obesity [36]. An
analysis of liver histology reveals that the prevalence rates of steatosis and steatohepatitis was
15% and 3% respectively in non-obese people, 65% and 20% respectively in people with
Class I and Class II obesity and 85% and 40% respectively in extremely obese people. The
relation between BMI and NAFLD is also found to be affected by factors like race, ethnicity
and genetics [34].

Fatty liver is a consequence of obesity and is associated with the change in function of AT
[37]. AT is the body tissue used for the storage of fat and is the only organ with unlimited
growth potential at any stage of our life. During obesity, adipose tissues expands by
increasing the number of adipocytes i.e. hyperplasia or by increasing in the size of adipocytes
i.e., hypertrophic growth [38]. AT stores excess energy as fat (triglycerides) in adipocytes,
the change in the function of triglycerides can lead to lipo-toxicity, from increased delivery of
fatty acids to non-adipose tissue [39]. This is a crucial factor in the development of hepatic
steatosis. Similarly, the endocrine function of adipose tissue has an impact on parenchymal
and non-parenchymal liver cells, leading to inflammation and fibrosis.

The first stage of NAFLD is the accumulation of lipids in the hepatocytes of the liver, also
known as steatosis. The process of de novo lipogenesis (DNL) should convert carbohydrates
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into fatty acids used for synthesizing triglycerides that leaves the liver during a normal lipid
metabolism. However, due to dyslipidemia, imbalance of lipids occurs and the accumulation
of lipids in the liver further intensified by dietary fat, altered fatty acid oxidation or
circulating fatty acids released from adipose tissue causing steatosis.

The second stage of NAFLD, also known as steatohepatitis/cirrhosis refers to large
hepatocyte cells injury, inflammation, and fibrosis, that all occurs from oxidative stress,
mitochondrial dysfunction, and insulin resistance. Oxidative stress arises due to lipid
peroxide in hepatocytes. Moreover, the deficiency of intestinal gluconeogenesis also induces
fatty liver disease that progresses towards inflammation and fibrosis [40]. The process of
gluconeogenesis comprises synthesis of glucose and glycogen from lactate, pyruvate,
glycerol and certain amino acids [41] in liver, which is important when the dietary supply of
glucose is not enough for metabolic demands. Especially during starvation or low
carbohydrate diet [42], such process is activated. It is also important in the removal of
excessive quantities of glucose precursors from the blood. The low gluconeogenic capacity
leads to low blood glucose concentrations, low insulin levels and high rates of fatty acid
metabolization causing severe hepatic lipidosis (disorder of lipid metabolism in body tissues)
[43].

Figure 2.1 illustrates a flowchart of management of NAFLD in association with obesity [44].
It indicates that, diet and physical exercise are the first recommended step for all patients.
Next, if the patients are unresponsive to the lifestyle modification carried out in the 1st step,
pharmacotherapy would be recommended selectively for the patients with BMI > 27. Finally,
the patients typically with BMI > 35 if do not show response to the 1 st and 2nd step, bariatric
surgery would be considered. This way, three different steps of recommendation in NAFLD
management are performed in obese patients.
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Another study also suggests that obesity could be controlled for NAFLD management,
targeting lifestyle management [44]. Orlistat and liraglutide are approved anti-obesity drugs
for NAFLD. Bariatric surgery for selected morbidly obese NAFLD patients.

Figure 2.1: A flowchart illustrating an obesity-oriented algorithm for the management of
NAFLD. (adopted from [44])

2.3 Pathway that leads to fatty liver

NAFLD is characterized by an accumulation of triglycerides in hepatocytes and strongly
associated with obesity, T2DM, hyperlipidemia, and insulin resistance [45]. However, the
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mechanism behind the triglyceride accumulation is not clearly understood [46-48]. Fatty
liver might induce steatosis, portal inflammation or degeneration of liver. Also, histological
changes like apoptotic bodies, mallory bodies, clear vacuolated nuclei, megamitochondria
and perisinusoidal fibrosis are common [49]. However, research shows that hepatic steatosis
progresses to steatosis resulting in inflammation and further injury [50]. Hormonal
imbalances, oxidative stress abnormalities in mitochondria are potential causes for this
phenomenon [51]. The pathogenesis is interpreted by the ‘double-hit’ hypothesis. The
primary hypothesis includes lipid accumulation in the liver, followed by proinflammatory
mediators that induce inflammation, hepatocellular injury, and fibrosis. Following this, the
FAs uptake from the adipose tissue takes place. There is further reduction in fatty acid
oxidation associated with NAFLD [52]. Despite the excess hepatic accumulation of FAs in
NAFLD, there is rise in de novo hepatic FA synthesis from glucose which also involves the
FAs, taken up from the serum and is characterized as the “first hit” for NAFLD development.
Further progression of NAFLD involves “parallel and multiple-hit” injuries including high
oxidative stress induced mitochondrial dysfunction, endoplasmic reticulum stress, endotoxininduced, TLR4-dependent release of inflammatory cytokines and iron overload [53]. The
combination of these parallel hit infers triggers several signal cascading which ultimately
leads to inflammation, cell death, and fibrosis. Such consequence is the ultimate stage of
NAFLD.

Furthermore, insulin resistance is a key pathogenic feature during metabolic dysfunction in
body, it is the common risk factor for NAFLD which also alters the glucose metabolism. [5456]. The decreased sensitivity of body tissues to insulin are categorized into systemic and
hepatic insulin resistances [56]. During the systemic insulin resistance, insulin cannot reduce
blood glucose levels due to the impaired translocation of GLUT4 receptor to the surface
membrane of the muscle cell resulting into the loss of insulin-dependent uptake of glucose.
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[57]. During hepatic insulin resistance, the insulin-induced suppression of hepatic glucose
production is interrupted [57]. Due to insulin resistance, hepatocytes lose insulin-mediated
autoregulation which increases the glucose production [58] through glycogenolysis and
gluconeogenesis as well as higher cholesterol and triglyceride synthesis [59].
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Chapter 3. PATERNAL OBESITY

3.1 Present statistics (World and the US)

According to Global Health Observatory (GHO) data published by WHO in 2016,
approximately half of the global population were either obese or overweight. The prevalence
of obesity among women was 15.1% as compared to 11.1% in men. Nevertheless, the
prevalence of obese and overweight males is much higher than that of females in some
regions. The gender gap has extended in several countries and the gap is more remarkable in
overweight than in obesity [60]. Table 3.1 – 3.3 show the prevalence of obesity among the
people of different regions of the world and within the US.

The rates of obesity within males of reproductive age has tripled worldwide since 1970 [61].
A survey published in the Journal of the American Medical Association in 2013 found that
71% men aged > 20 were overweight and 31% were obese [62]. The same survey conducted
in 1970 had found that 47% of men were overweight and 15% were obese. Hence, the
prevalence of obesity among American males has doubled within 25 years.
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Table 3.1: Prevalence of overweight individuals in 1975 and 2016 by WHO region and sex.
Source: WHO Global Health Observatory, 2016 [62]

Note: Values are presented as median (range).
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Table 3.2: Prevalence of overweight individuals in 1975 and 2016 by World Bank income
groups (low, lower-middle, upper-middle and high) and sex Source: WHO Global Health
Observatory, 2016 [62]

Note: Values are represented as median (range).
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Table 3.3: Estimated (Age-adjusted) Percentage of US adults with overweight and obesity by
sex, 2013-2014. Source: National Health and Nutrition Examination Survey (NHANES) [63]

3.2 Implications of paternal obesity in fertility

Similar to the effect of maternal obesity, obesity in the father has adverse effect on offspring
and also introduces substantial effect on trans-generational programming of their offspring
[64, 65]. Risk factors due to the father, including obesity, diabetes mellitus, nutritional and
dietary habits (high-fat and low-protein diet, undernutrition), habits of smoking, substance
abuse, etc. are found to clearly affect the metabolic and cardiovascular health of their
offspring [64]. Pre-conceptional risk factors in the father mediate through sperm RNAs for
programming offspring phenotypes [65]. Alteration in sperm epigenetics including sperm
DNA methylation and acetylation leading to abnormal cellular response to stress, cell death
and growth in adipose tissue of consecutive generations are found to be the mechanism of
paternal obesity programming [64]. Such programming of father’s obesity in offspring is
shown to impair the adipokine levels in offspring up to next two generations [64, 66, 67].
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Paternal obesity has a negative impact on fertility, subsequent pregnancy and offspring health
as it alters sex hormones and molecular composition and function of spermatozoa [68].
Obesity in males is found to reduce sex hormone-binding globulin and testosterone levels
while increasing estrogen levels, directly impairing spermatogenesis [68]. It even reduces
sperm counts accounting for increasing incidence of oligospermia and azoospermia. Fig. 3.1
depicts a flow chart explaining the summary of the mechanism through which paternal
obesity effects the offspring. Both human and rodent models show that paternal obesity
impairs sex hormones, basic sperm function and molecular composition, thereby impairing
embryo development and health following increased offspring disease burden in both sexes.

Figure 3.1 Flowchart illustrating the overall effects of paternal overweight or obesity on
offspring health and development via the medium of alteration in sperm and embryo.
(adopted from [61])
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Obesity in the male parent has been found to not only increase the incidence of infertility, but
also significantly increase the risk of metabolic alterations in adult offspring [69]. Another
study has also revealed that diet-induced obesity and altered glucose homeostasis in the father
can impair the metabolic health of female offspring [70]. However, one study showed no
association between paternal BMI and infant birth size [71]. Paternal obesity impairs preimplantation and embryo development but does not influence gross fetal or placental
morphology [72].

Research from National Institutes of Health (NIH)’s has shown the connection between
paternal obesity and risk of liver diseases in offspring. It was found that obese fathers have an
elevated level of serum alanine aminotransferase (ALT), a liver enzyme in comparison to
non-obese fathers. Also, a child’s ALT level is shown to be strongly associated with the
father’s obesity with higher ALT among individuals with paternal obesity [73]. Higher ALT
induces larger injury in hepatocytes which acts as a precursor to steatosis.

3.3 Nutritional and Lifestyle Intervention

In this section, a few of the recent advances achieved in the study of nutritional and lifestyle
intervention in paternal obesity are discussed in detail. The comprehensive understanding of
the past work will provide framework for the present experimental work in paternal obesity.

Similarly, Ost et al. [74] has introduced a Drosophila model of paternal-diet-induced
Intergenerational metabolic reprogramming (IGMR). The IGMR phenotype consists of two
characteristics: F1 offspring body weight increased with paternal dietary sugar intake
however, the triglyceride level was comparable between offspring of fathers fed high sugar as
well as low sugar. Another study conducted by Zhou et al. [75] identified effects of dietinduced paternal obesity on cognitive function in mice offspring. They identified that paternal
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obesity did not affect body weight, adiposity and serum metabolism in offspring however, it
resulted in cognitive impairments in F1 offspring in the hippocampus at 8 weeks of age.

Another study by Fullston et al. [69] determined the effect of diet-induced paternal obesity,
in the absence of diabetes, on the metabolic health of two resultant generations and the
molecular profiles of testes and sperm. They found that HFD induced obesity with 21%
adiposity, impaired glucose tolerance in both male and female offspring and induced obesity
in females and hyper-leptinemia in males. Another study by Fullston et al. [76] identified that
the preconception paternal exposure to HFD impairs the metabolic and reproductive health of
male offspring. It was observed that the sperm ROS concentrations and the sperm oocyte
binding were detrimental in the offspring of HFD fed father. Further, the metabolic and
fertility disturbances in male offspring impaired by the HFD father are found to be
aggravated by a “second hit” of obesogenic environment postnatally. Such alteration in sperm
function and physiology in obese mice fathers as a result of elevated oxidative stress in
spermatozoa was also identified by Bakos et al. [77]. Such high oxidative stress mostly
results in sperm DNA damage and loss of function. In their study, they found that the motile
spermatozoa were higher in HFD group as compared to CD group (36%, p<0.05), the
intracellular ROS was elevated (692 vs. 409 units, p < 0.01) and the sperm DNA damage was
also higher (1.64 vs. 0.17, p < 0.05). Batista et al. also performed interventional study on
mice by dividing male mice into two groups: CD fed sedentary and CD fed swimming
(exercise) group [78]. After the exercise intervention for 6 weeks, they were allowed to mate
with sedentary female mice and offspring were studied. The offspring born to the exercise
group showed lower body weight than the sedentary counterparts. They also found that the
offspring corresponding to the exercise fathers showed lower levels of gene expression of
Fasn and Acaca and higher level of AMPK protein in the testes demonstrating the clear
differentiation in terms of molecular parameters. The gene expression of Prkaa2, Ppar1a, and
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Cpt-1 were also higher in male offspring liver from the exercise group. They demonstrated
that paternal exercise training can improve the metabolic profile in the offspring and also
elucidated the bio-chemical pathways in liver and testes.

Similarly, a study by McPherson et al. also suggests preconception diet and exercise
intervention in obese father normalizes the sperm profile which ultimately reduces the risk of
metabolic syndrome in offspring [79]. They performed experiments with the mouse model to
demonstrate the paternal dietary and exercise intervention to find its effect on offspring. The
intervention was performed to cross over at least 2 rounds of spermatogenesis (i.e., 8 weeks)
in obese males (fathers) with an aim to normalize anomalous epigenetic signals in sperm. It
was found to restore lower adiposity as well as to normalize the insulin sensitivity in
offspring. The pathway to such improvement was understood by studying the abundance of
X-linked sperm microRNAs which target genes regulating cell cycle and apoptosis during
early embryogenesis. Their findings also shed light on intervention window for the
improvement in offspring which can be a novel circuit breaker for the intergenerational
intensification of obesity and metabolic dysfunction.

With an aim of comprehending the effect of parental obesity on embryo development,
Mitchell et al. [72] carried out an investigation of preimplantation embryo development and
implantation rate on the diet-induced obese mice. After the CD and HFD fed male mice were
mated with CD fed female mice, zygotes were collected and cultured to the blastocyst stage
which were then examined before transferring into recipient females. They observed that the
embryos from obese males had reduced cleavage and slower development to blastocyst stage
during culture as compared to the CD males. Furthermore, a study on the effect of paternal
diet induced obesity on retarding of the embryo development and mitochondrial activity was
also performed by Binder et al [80] . By employing IVF technique, they isolated the
29

functional effects of obesity on sperm by investigating the embryo both pre- and postimplantation in mice. Paternal obesity was found to be associated with significant delay in
embryo development as well as reduction in mitochondrial membrane potential. Detailed
examination showed that blastocysts derived from sperm of obese males showed significantly
reduced outgrowth on fibronectin in vitro following a slower fetal development in vivo (after
embryo transfer). Both of these studies [72, 80] clearly demonstrated the effect of father’s
obesity on preimplantation and implantation of embryo highlighting the role of father’s role
for achieving a viable pregnancy.
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Chapter 4. FISH OIL SUPPLEMENTATION

4.1 Fish Oil

Fish oil contains two types of omega-3 fatty acids, docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA). DHA and EPA are found in oily fish such as trout, salmon,
shark, mackerel, pilchards, sprats, albacore tuna, anchovies, sword fish and sardines as well
as krill and some shellfish. Plant derived alpha-linolenic acid (ALA) are found in seeds and
oils including flaxseed, walnuts, chia, hemp and some vegetable oils. These FAs are
important nutrients for bodily functioning, particularly brain functioning, due to their antiinflammatory, anti-thrombotic and vaso-dilatory properties [81]. DHA and EPA are long
chain polyunsaturated fatty acids (PUFA) which have strong positive association with human
health. However, intake of such fatty acids is very low in our daily food habits which might
result in adverse health effects [82]. Fish oils are good available source of unsaturated
straight-chain fatty acids, ranging from C14 to C22, having 1 to 6 double bonds. Further, it
has been shown that omega-3 can reduce the risk of heart disease and hypertension, prevent
blood clots, protect against cancer, and even protect against depression [83, 84]. The World
Health Organization (WHO) recommends eating 1-2 portions of fish or fish supplements per
week. A minimum daily intake of 500 mg of EPA and DHA has been recommended by the
Global Organization for EPA and DHA Omega-3s [85]. Some fish oil products are approved
by the US Food and Drug Administration (FDA) as prescription medications to lower
triglycerides levels.

4.2 Effects of fish oil consumption

The effects of fish oil consumption are greater in adults with higher triglyceride levels
(>1000mg/dL) or hypertriglyceridemia as it is expected to reduce triglyceride levels by 20 to
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50% [86]. However, it is not very effective for children and teens. Also, the triglyceride
lowering effect is not seen with plant derived ALA [87]. The supplement is an important
therapeutic option also for patients with type V hyperlipidemia which is characterized by
elevated plasma chylomicrons and TG > 1000 mg/dL [88].

4.3 Fish oil to treat metabolic disorders

Obesity often causes dyslipidemia, insulin resistance, and metabolic syndromes and it has
been determined as the main pathogenic mechanism associated with these conditions [85]. A
study in New Zealand in 2018 has shown that users take fish oil supplements for ‘general
well-being’ (72.6%), to ‘improve brain functioning’ (54.8%), for ‘pain/inflammation’
(31.5%), and to ‘lower cholesterol levels’ (12.3%) and for ‘dietary insufficiency’ (11%),
indicating that fish oils are used to both prevent and treat health conditions. The majority of
fish oil users in this same survey reported taking a supplement that contained 1000 mg of fish
oil equivalent to 120 mg of DHA and 180 mg of EPA per capsule. This means that a dose of
at least 2000 mg of fish oil per day would be required to meet the National Heart foundation
recommendations of 400–600 mg DHA and EPA [81]. A trial in rabbits was shown to lower
body weight by 36% and intra-abdominal adipose tissues by 16% in FO fed rabbits [85].

However, a meta-analysis reported that n-3 PUFA had no effects on insulin sensitivity [89].
Another meta-analysis [90], based on 672 participants from 17 studies, although showed no
significant effect of fish oil supplementation on insulin sensitivity in overall, a subgroup
analysis indicated that the supplementation could reduce the risk of insulin resistance by 47%
among participants with metabolic disorders. This highlights the benefits of fish oil
supplementation especially on the patients with metabolic syndrome. The study also
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suggested that short-term fish oil supplementation (less than 12 weeks but at least over 4
weeks) was beneficial for insulin sensitivity than long-term intervention [90].

4.4 Fish oil and Fatty liver

A study based on RCT illustrates that 6 months of fish oil supplementation has no effects on
glycemic control, but has shown improvement in triglyceride and high-density lipoprotein
cholesterol (HDL-C) in T2DM patients with abdominal obesity [91]. A pilot study to evaluate
the effect of fish oil supplementation in a randomized, double-blind, placebo-controlled
clinical study was performed by Cansancao et al. [92] on NAFLD patients. After providing
either placebo or fish oil supplementation for 6 months, circulating miR-122 expression, liver
fibrosis, RBCs fatty acids (gas chromatography) and biochemical tests were performed. They
found that DHA and omega index was significantly higher in RBCs, and alkaline phosphatase
as well as liver fibrosis were reduced in fish oil supplemented individuals. They concluded
that fish oil was incorporated in erythrocytes after six months of fish oil supplementation
which was effective in reducing fibrosis in NAFLD patients.

Similarly, fish oil interventional study on mice conducted by Yamazaki et al. [53] also
showed that fish oil completely prevented the sucrose-induced fatty liver which would
otherwise be exacerbated in sucrose fed mice as compared to control group mice. They found
that, sucrose in diet increased the sterol regulatory element-binding protein 1 (SREBP-1c),
while intervention with fish oil completely inhibited such rise in SREBP-1c.

In order to further comprehend the underlying protein mechanisms of fish oil in protecting
against NAFLD, Yuan et al. [93] also performed experiment on male Sprague-Dawley rats.
They provided either high-fat and high-cholesterol diet (WD) or a WD diet supplemented
with fish oil (FOH) to male rats for 16 weeks and examined the histological and biochemical
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factors to compare the development of liver steatosis and fibrosis among two different
groups. The rats in FOH group showed significantly lower WD-induced dyslipidemia,
hepatic steatosis, inflammatory infiltration, and fibrosis. They identified that the long term
intake of fish oil corrected the expression levels of genes involved in fatty acid and
cholesterol metabolism including Srebf1, Fasn, Scd1, Insig2, Cd36, and Pcsk9. Further, the
expression of proinflammatory genes Mcp1, Socs2, Sema4a, and Cd44 in the FOH group was
lower than that in WD group rats clearly demonstrating the molecular metabolism involved in
the role of fish oil in preventing NAFLD.

Fish oil suppresses body fat accumulation and alters the expression of genes related to fatty
acid synthesis in the liver and intestine, as shown in the research done in zebrafish. Fish oil
diet group had less body fat accumulation in 4 weeks compared with fish in the lard diet
group [84].
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Chapter 5. METHODOLOGY

The present research focuses on identifying potential benefits of FO supplementation in
males during the preconception period and its beneficial effects in reducing obesity in the
offspring by lowering obesity-associated inflammation and lipid metabolism in liver.

For the purpose of the study, I will test the working hypothesis by first establishing the
potential benefits of n-3 PUFAs with phenotypic tests in offspring followed by mechanistic
studies in the tissues. These results provide a vertical leap in the knowledge base regarding
the benefits of n-3 PUFAs supplementation in fathers for beneficial effects in offspring.
Additionally, this study would be a first to identify if FO supplementation is required by men
during their preconceptual period.

Investigating the direct effect of an obese father (initial generation denoted by ‘F0’) on a
child (next generation denoted by ‘F1’) in human subjects would take enormous time to gain
results and understand the phenomenon. The proposed study can experimentally be carried
out in mice. A mouse would sexually mature within 35 days of birth and can reproduce up to
5-7 times a year, each time birthing 5 to 10 pups. Thus, we chose this path to accomplish the
study which would lay the foundation for future human research studies. Details of mice
bought from Jackson Laboratory is provided in next section.

5.1 Obesity induction in F0 male mice

I applied one of the commonly utilized methods of high fat diet (HFD) for induction of diet
induced obesity. Male mice purchased from Jackson laboratory (n = 30) after a week of
acclimatization were randomly divided into three groups each n = 10: control group with low
fat diet (CD: 10, 20 and 70% energy from fat, proteins, and carbohydrates, respectively), and
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experimental group with high fat diet without (HF: 45, 20, 35% energy from fat, proteins, and
carbohydrates, respectively) or with fish oil supplementation (HF-FO: 36 g/kg of fish oil
containing equal quantities of EPA and DHA). Details of the diet composition corresponding
to CD, HF and HF-FO diets are also provided in Table 5.1. We chose this dose based on the
previous studies [94, 95]. To minimize the effect of any other diet components, the amount of
protein, minerals, and vitamins required were kept equal for both groups, thus implying
overall higher calorie intake to HF or HF-FO mice compared to CD mice. The purpose of
dyes is to differentiate the mice food visually while providing it to the mice of corresponding
dietary groups.

Mice were fed with respective diets for 10 weeks to mimic paternal obesity in male mice and
the mice were housed in wire mesh cages provided with wood bedding. In order to simulate
the natural environment, the temperature is maintained at 20 oC with 12 hour light and dark
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Table 5.1: Diet Composition (Formulated by Research Diets, Inc.)
High Fat – Fish

Control- Low
High Fat
Fat

Oil

gm%

kcal%

gm%

kcal%

gm%

kcal%

Protein

28

28.5

34

28.5

34

28.5

Carbohydrate

57

58.0

31

27

31

27

Fat

6

13.5

24

45

24

45

Total

100

100
4.7

100

kcal/gm

3.92

4.7

Ingredient

gm

kcal

gm

kcal

gm

kcal

Casein, 30 mesh

286.1

1144

286

1144

286

1144

L-Cystine

3

12

3

12

3

12

Corn Starch

330

1320

11.8

47

11.8

47

Maltodextrin 10

75

300

75

300

75

300

Sucrose

172.8

691

172.8

691

172.8

691

Cellulose

50

0

50

0

50

0

Soybean Oil

25

225

25

225

25

225

Lard

36

324

177.5

1598

134.6

1211

MEG-3 Ultra High EPA

0

0

0

0

42.91

386

Mineral Mix, S10026

10

0

10

0

10

0

DiCalcium Phosphate

13

0

13

0

13

0

Calcium Carbonate

5.5

0

5.5

0

5.5

0

EE oil (720 mg/g EPA)
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Potassium Citrate, 1

16.5

0

16.5

0

16.5

0

Vitamin Mix, V10001

10

40

10

40

10

40

Choline Bitartrate

2

0

2

0

2

0

Vitamin E Acetate, 50%

0

0

0.13

0

0.13

0

FD&C Yellow Dye #5

0

0

0

0

0.05

0

FD&C Red Dye #40

0.05

0

0.025

0

0

0

FD&C Blue Dye #1

0

0

0.025

0

0

0

Total

1034.95 4057

858.28

4057

858.29

4057

H2O

(500 IU/gm)

5.2 F0 (Father/Mother) Mice and Mating

Male F0 mice were divided into three groups of dietary intervention LF (n = 8), HF (n = 10),
FO (n = 10) and the respective diet was fed for 10 weeks. The weekly measurement of F0
male mice weight as well as their weekly food consumption was carried out and recorded.
For mating, each F0 male mice were individually housed with 10 weeks old female mice in
cage. All female mice were fed LF. The male and female F0 mice pairs were continued to be
kept in cage for 3 weeks to ensure conception. LF diet was fed to all mice during the 3 weeks
window. Female mice were physically inspected multiple times and once conception was
confirmed, they were separated from their respective male companion. Following the
conception, females were fed with LF only. F1 offspring were born after the gestation period
of 3 weeks. F0 male mice were sacrificed after F1 were born.
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5.3 F1 (Offspring mice) selection and body weight measurements

After F1 were born, their birth weight was recorded, and they were kept with F0 female till
weaning which was performed at 3 weeks of age. After weaning, body weight of F1 mice was
recorded and F0 female was sacrificed. Out of all F1 mice, certain number of mice offspring
of LF, HF, and FO fed fathers were selected randomly for further study, the exact numbers
(n) are shown in Results and Discussion Chapter. The F1 mice (offspring) were fed with
regular chow diet (LF) throughout and weekly measurement of their body weight as well as
food consumption was performed. Out of the selected offspring of each group, half were
randomly selected for sacrifice at 8 weeks and the remaining half were sacrificed at 16 weeks
to understand the short- and long-term effects of paternal obesity.

5.4 Metabolic tests

Phenotypic metabolic tests including glucose and insulin tolerance tests were performed on
the F1 male offspring at 12 weeks of dietary intervention. Only mice which were on dietary
intervention until 16 weeks (long term) were used for these tests. After five hours of fasting,
blood glucose was measured using a handheld glucometer. Initially, 2 gm/kg glucose was
injected intraperitoneally, following which, blood glucose was measured at 30, 60, 90 and
120 minutes. Similarly, for insulin tolerance tests (ITT), 1 IU insulin/kg was injected after
five hours of fasting and blood glucose measured.

The glucose tolerance test measures the clearance of an intraperitoneally injected glucose
load from the body. It was used to detect disturbances in glucose metabolism that can be
linked to T2D or metabolic syndrome. Animals were fasted for 5 hours; fasted blood glucose
levels were determined before a solution of glucose is administered by intra-peritoneal (IP)
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injection. Subsequently, the blood glucose level was measured at different time points during
the following 90 minutes.

5.5 Histology

After sacrifice at 8 weeks as well as in 16 weeks, adipose tissue, liver, and muscle tissue were
harvested along with blood and other tissues. The primary focus of this thesis is the study of
liver tissue and blood of the male offspring belonging to different dietary groups. A separate
part of liver tissue was also separated and stored in Z-fix and then embedded with paraffin
followed by staining with hematoxylin and eosin. Such tissues were taken to capture images
from microscope. From the 20x magnified images of liver tissue, an analysis of liver tissue
was conducted.

5.6 Obesity markers measurement

We also measured serum insulin, leptin, adiponectin to assess adiposity. Additionally,
triglyceride and cholesterol levels were measured in the blood. Liver tissue stored in -80oC
was taken out and cut over a piece of dry ice to obtain a slice which was later utilized for
RNA isolation. RNA was isolated by following the protocol provided in Appendix A1. Once
prepared, RNA concentration was measured using nanodrop. Later, the prepared RNA was
stored in -80oC until cDNA preparation. cDNA preparation from the isolated RNA was
carried out using high-capacity kit from Applied Biosciences and the steps involved in shown
in Appendix A2. Finally, gene expression of cDNA was carried out using qPCR by using
corresponding primer. The mixtures (provided in Appendix A3) were kept in PCR plate and
run in QuantStudio3 PCR machine. Once the results were obtained, data analysis of relative
quantification of genes corresponding to the offspring of different dietary groups was
performed.
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Further, the table below illustrates the detail about the markers of interest, their role in
metabolism and their expected outcomes in terms of FO supplementation.

Table 5.2: Biomarkers of interest in the present study along with their role and
expected outcome.
Markers

Role

Expected Outcome

Il-6

Pro-inflammatory

Paternal FO supplementation will

marker

reduce IL-6 expression in
offspring

mTOR

Pro-inflammatory

Paternal FO supplementation will

marker

reduce mTOR expression in
offspring

TNF-a

Pro-inflammatory

Paternal FO supplementation will

marker

reduce TNF-a expression in
offspring

Fatty acid synthase (FASN)

Fatty acid synthesis

Paternal FO supplementation will
reduce FASN expression in
offspring

SREBP-1c

Fatty acid synthesis

Paternal FO supplementation will
reduce SREBP-1c expression in
offspring
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mCD36

Fatty acid synthesis

Paternal FO supplementation will
reduce mCD36 expression in
offspring

mFOXO

Fatty acid oxidation

Paternal FO supplementation will
upregulate mFOXO expression in
offspring

CPT-1

Fatty acid oxidation

Paternal FO supplementation will
upregulate CPT-1 expression in
offspring

PPAR- γ

Fatty acid synthesis

Paternal FO supplementation will
upregulate PPAR- γ expression in
offspring

G6P

Gluconeogenesis

Paternal FO supplementation will
reduce G6P expression in
offspring

mPDK4

Gluconeogenesis

Paternal FO supplementation will
upregulate mPDK4 expression in
offspring
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5.7 Statistical analysis

First, the body weight of father (F0) and male offspring (F1) was obtained on weekly basis
which was compared among different groups by considering mean ± SEM. Furthermore, to
understand the implication of obese fathers on the overall health and development of F1
offspring, comparisons of metabolic test results and gene expression relative quantification
(RQ) among different groups were performed and the level of significance (p) was calculated.
1-way ANOVA was opted to investigate the effect of diet difference among male offspring
belonging to different dietary groups.
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Chapter 6. RESULTS AND DISCUSSION

6.1 F0 Male Mice Body Weight

The body weight of F0 male mice was recorded weekly. Figure 6.1 shows the body weight of
F0 father mice from weeks 1 to 11. The average body weight of offspring of fathers of each
dietary group is considered for comparison. LF mice had significantly lower average body
weight as compared to HF and FO mice especially after 5 weeks of intervention (p < 0.05) as
indicated by different letters on the plot in Fig. 6.1. Furthermore, the quantity of weekly food
consumption by F0 male mice kept into three different dietary intervention was comparable
as shown in Fig. 6.2 which shows that the difference in body weight observed in Fig. 6.1 is
due to high-fat content on HF and FO diet as compared to LF diet rather than inconsistent
quantity of food consumed.

Father Body Weight
Body Weight (gms)
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a
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9 10 11

a
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2

Weeks
LF Father

HF Father

FO Father

Figure 6.1 Body weight of father mice (F0) of three dietary groups over 12 weeks: LF (n =
8), HF (n = 11), FO (n = 11). Data presented is mean ± SEM (p < 0.05).
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Father Food Consumption
Weekly Food
Consumption (gms)
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Figure 6.2 Weekly food consumed in father mice (F0) of three different dietary groups: LF (n
= 8), HF (n = 11), FO (n = 11). Data presented is mean ± SEM (p < 0.05).

6.2 Offspring Body Weight

After the offspring (F0) were born (n = 217), their individual weight from each group was
recorded on their day of birth as well as a week after birth. Figure 6.3 shows the average
weight of pups belonging to the corresponding group of fathers fed with LF, HF and FO on
Day 1 and Day 7. On Day 1, it was found that male and female offspring of HF fed fathers in
average had significantly higher body weight as compared to offspring of LF fed fathers.
Similarly, average weight of male and female offspring of FO fed fathers was significantly
lower than the offspring of HF fed fathers. However, on Day 7, LF and HF offspring body
weight were similar, and the FO offspring was lower than the other two groups. From Figure
6.3, it illustrates that body weight of offspring should be monitored for longer duration of
time to see the short-term as well as long-term effect of dietary intervention of father.
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Offspring Day 1
Body Weight (gms)
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(a)

3

a
b

2
1
0

FO

a

LF

HF
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Figure 6.3 Average weight of offspring (F1) at day 1 and day 7. (a) Body weight at day 1 of
offspring of the fathers fed with LF (n = 49), HF (n = 78), and FO (n = 89) and (b) Body
weight at day 7 of offspring of the fathers fed with LF (n = 42), HF (n = 71), and FO (n =
73). Data presented is mean ± SEM (p < 0.05). Common letters indicate no significance.

Mice were weaned at three weeks of age. At 3 weeks of age, out of 217 born F1 offspring,
only 173 survived. Out of 173 offspring after identifying their sex, following were viable at
weaning: male offspring of LF fed father (n = 17), female offspring of LF fed father (n = 24),
male offspring of HF fed father (n = 34), female offspring of HF fed father (n = 31), male
offspring of FO fed father (n = 36), female offspring of FO fed father (n = 31). From the
available population, pups belonging to each dietary group of fathers and each sex were
randomly selected to categorize into short-term (ST) and long-term (LT) groups to see the
effect of paternal obesity and intervention on short-term and long-term life of offspring. For
ST group, male offspring of LF fed father (n = 8), female offspring of LF fed father (n = 10),
male offspring of HF fed father (n = 10), female offspring of HF fed father (n = 8), male
offspring of FO fed father (n = 10), female offspring of FO fed father (n = 10) were selected
and individually caged. Similarly, for LT group of offspring, male offspring of LF fed father
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(n = 8), female offspring of LF fed father (n = 10), male offspring of HF fed father (n = 14),
female offspring of HF fed father (n = 13), male offspring of FO fed father (n = 14), female
offspring of FO fed father (n = 13) were selected. Remaining pups were sacrificed and not
considered for further study. Figure 6.4 shows the variation of body weight of male and
female pups belonging to different dietary group of fathers during the initial stage of life.
Average body weight of offspring in both ST and LT groups is shown in these plots (Fig. 6.4
(a-b)) since all were available till the end of week 8.

Female pups 3 - 8 wks

Male pups 3 - 8 wks
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Body Weight (gms)

Body Weight (gms)
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FO
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Figure 6.4 Average body weight of male and female offspring (F1) after weaning at week 3
considering all mice on ST and LT groups from week 3 to week 8. (a) Male pups of LF (n =
16), HF (n = 24), and FO (n = 24) fed fathers. (b) Female pups of LF (n = 20), HF (n = 21),
and FO (n = 23) fed fathers. Data presented is mean ± SEM (p < 0.05).

Mice of the ST group offspring were sacrificed at the end of week 8, measurement of body
weight of LT group was carried on until week 16. The plots in Fig. 6.5 shows the body
weight of male and female pups belonging to different dietary group of fathers in LT group
only. No significant differences were observed in the average body weight of male pups of
HF fed fathers and those of LF fed fathers. Nevertheless, a significant difference in average
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weight of male pups of FO fed father as compared to other two groups was observed as
shown in Fig. 6.5 (a). Figure 6.5 (b) shows the average body weight of female pups from
week 9 to week 16 where no significant difference in body weight was identified. It is evident
that the effect of dietary intervention on father is more apparent in the male offspring as
compared to female offspring hinting the sex-based differences in epigenetic methylation.
Such sex-based gene imprinting for offspring was also revealed by past researchers [94, 97,
98].
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Figure 6.5 Average body weight of offspring (F1) assigned to LT group only (after ST group
were sacrificed at week 8) starting from week 9 to week 16. (a) Male pups of LF (n = 8), HF
(n = 14), and FO (n = 14) fed fathers. (b) Female pups of LF (n = 10), HF (n = 13), and FO
(n = 13) fed fathers. Data presented is mean ± SEM (p < 0.05). Common letters indicate no
significance.
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6.3 Glucose Tolerance Test (GTT) and Insulin Tolerance Test (ITT)

Male Offspring GTT
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Figure 6.6 GTT of male offspring (F1) of LF (n = 8), HF (n = 14), and FO (n = 14) fed
fathers performed at 12 weeks age. (a) Measured blood glucose level with time. (b) GTT
AUC at 150 minutes. Data presented is mean ± SEM (p < 0.05). Common letters indicate no
significance.

Figure 6.6 shows the results of GTT on male offspring. For the GTT, mice offspring (F1)
were fasted for 5 hours. Following this, blood glucose level was first measured using
handheld glucometer. At 0 minutes, 2 gm/kg glucose was injected intraperitoneally, and
blood glucose was measured at 15, 30, 60, 90, and 120 minutes with results illustrated in Fig.
6.6. As shown in Fig. 6.6 (a), after the glucose injection, the average blood glucose level in
male offspring of HF fed father was significantly higher than that of offspring of LF fed
father at 30 and 60 minutes. Furthermore, blood glucose level of male offspring of FO fed
father was significantly lower than that of HF fed father at 30 and 60 minutes. Clearly, the
average blood glucose level in HF male offspring was much higher than other two groups
after glucose injection. Later, blood glucose level started to stabilize and no significant
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difference in the glucose level on male offspring of LF, HF, or FO fed fathers was observed
90 and 120 minutes. Additionally, GTT AUC in Fig. 6.6 (b), showed that glucose intolerance
was increased in male offspring of HF fed father compared to male offspring of LF fed
father. Further, male offspring of FO fed father had significantly lower glucose intolerance
compared to offspring of HF fed father.
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Figure 6.7 GTT of female offspring (F1) of LF (n = 10), HF (n = 13), and FO (n =13) fed
fathers performed at 12 weeks age. (a) Measured blood glucose level with time. (b) GTT
AUC. Data presented is mean ± SEM (p < 0.05). Common letters indicate no significance.

Similarly, in Fig. 6.7, blood glucose levels of female offspring of HF fed father was
significantly higher than female offspring of LF fed father after 30 minutes of glucose
injection (see Fig. 6.7 (a)). Moreover, blood glucose levels of female offspring of FO fed
father was significantly lower than female offspring of HF fed father 30 minutes after
injection. However, no significant differences in blood glucose level of female offspring at
60, 90, and 120 minutes were observed. GTT-AUC plot shown in Fig. 6.7 (b) also illustrates
an impaired glucose tolerance in female offspring of HF fed father compared to offspring of
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LF fed father. Further, significantly higher glucose tolerance was observed in female
offspring of FO fed father compared to female offspring of HF fed father. Combined, Fig. 6.6
and 6.7 highlights the effectiveness of FO supplementation during paternal obesity on reestablishing the glucose tolerance in male and female offspring.
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Figure 6.8 ITT of offspring (F1) performed at 14 weeks age. Blood glucose level with time (a)
Male offspring of LF (n = 8), HF (n = 14), and FO (n = 14) fed fathers. (b) Female offspring
of LF (n = 10), HF (n =13), and FO (n = 13) fed fathers. Data presented is mean ± SEM (p <
0.05). Common letters indicate no significance.

Next, for insulin tolerance tests (ITT), 1 IU insulin/kg was injected after five hours of fasting
in male and female offspring and blood glucose level was measured at different time points.
As illustrated in Fig. 6.8 (a), average blood glucose level in male offspring of HF fed father
was significantly higher than that of offspring of LF fed father at time 30, 45, 60, 90, and 120
minutes. Similarly, blood glucose level of male offspring of FO fed father was also
significantly lower than that of male offspring of HF fed father throughout 120 minutes.
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Figure 6.8 (b) shows that blood glucose levels of female offspring of LF, HF, and FO fed
fathers do not show significant difference from 0 to 45 minutes. However, at 60, 90, and 120
minutes, significantly higher blood glucose levels were observed in female offspring of HF
fed father compared to female offspring of LF fed father. Similarly, female offspring of FO
fed father showed significantly lower blood glucose level than female offspring of HF fed
father at 60, 90, and 120 minutes indicating better insulin sensitivity. From the plots in Fig.
6.8 (a, b), male and female offspring of HF fed father were found to be insulin resistant as
compared to offspring of LF fed father and FO supplementation during paternal obesity
prevented the risk of insulin tolerance in both male and female offspring. Furthermore, the
delay in the time instant of significant difference in blood glucose level in female offspring
(at 60 minutes) as compared to the male offspring (at 30 minutes) reiterates the potential sexbased DNA imprinting on mice offspring.
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6.4 Liver
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Figure 6.9 Liver tissue weight of offspring sacrificed at 8 weeks (ST group). (a) Male
offspring of LF (n = 8), HF (n = 10), FO (n = 10) fed fathers. (b) Female offspring of LF (n
= 10), HF (n = 8), FO (n = 10) fed fathers. Data presented is mean ± SEM (p < 0.05).
Common letters indicate no significance.
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Figure 6.10 Liver tissue weight of offspring sacrificed at 16 weeks (LT group). (a) Male
offspring of LF (n = 8), HF (n = 14), and FO (n = 14) fed fathers. (b) Female offspring of LF
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(n = 10), HF (n = 13), and FO (n = 13) fed fathers. Data presented is mean ± SEM (p <
0.05). Common letters indicate no significance.

The impaired metabolic pathways in offspring of obese father are linked with liver
metabolism and inflammation. Liver weight of mice sacrificed at 8 weeks (ST group) and 16
weeks (LT group) are shown in Fig. 6.9 and 6.10 respectively. In terms of liver weight, no
significant differences were observed among the male and female offspring of fathers fed
with LF, HF, and FO sacrificed at 8 weeks of age (ST group). Such insignificance was
consistent even during the latter stage of life as revealed from the liver weight of male and
female offspring sacrificed at 16 weeks (LT group) in Fig. 6.10. Thus, the liver weight alone
cannot explain the paternal obesity induced difference in metabolic alteration or possible liver
inflammation. Therefore, we proceeded to further investigation of liver tissue through
microscopic imaging and genomic approaches.
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(a)

(b)

(c)

Figure 6.11 Liver tissue viewed under microscope extracted from male offspring of (a) LF,
(b) HF, (c) FO fed fathers and sacrificed at 16 weeks of age. Larger fat deposition is
observed in the liver of male offspring of HF fed father.

55

(a)

(b)

(c)

Figure 6.12 Liver tissue viewed under microscope extracted from female offspring of (a) LF,
(b) HF, (c) FO fed fathers and sacrificed at 16 weeks of age. Larger fat deposition is
observed in the liver of female offspring of HF fed father.
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Figure 6.11 and 6.12 illustrate the histology of liver tissues of male and female offspring
respectively. As illustrated in Fig. 6.11, more fat deposits were observed in male offspring of
HF fed father (see Fig. 6.11(b)) as compared to male offspring of LF fed father (see Fig.
6.11(a)). Fat deposits in liver was diminished in male offspring of fathers with FO
supplementation compared to offspring of HF fed father (Fig. 6.11(c)). Histology of liver
tissues in male offspring clearly shows the effect of paternal obesity as well as the benefits of
FO supplementation to father during preconception period.

Similarly, Fig. 6.12 shows similar histology of liver in female offspring of LF, HF, and FO
fed fathers. However, the effect of paternal obesity and FO supplementation in liver was not
as apparent in female offspring as in male.

6.5 Gene Expression in Liver of Male Offspring

In order to understand the observed changes in lipid metabolism and inflammation in liver,
expression of proinflammatory markers interleukin 6 (IL6), tumor Necrosis factor alpha
(TNF-a), and mammalian target of rapamycin (mTOR) were analyzed. Similarly, fatty acid
markers: fatty acid synthase (FASN), sterol regulatory element-binding protein 1 (SREBP1c), cluster of differentiation 36 (CD36), forkhead box transcription factor (FOXO), carnitine
palmitoyl transferase 1 (CPT-1) and peroxisome proliferator-activated receptor gamma
(PPAR-γ) were analyzed. The markers of gluconeogenesis and lipogenesis pyruvate
dehydrogenase kinase (PDK4), and glucose-6-phophate dehydrogenase (G6P) were also
studied.
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6.5.1 Liver biomarkers of offspring at 8 weeks (ST)
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Figure 6.13 Relative expression of pro-inflammatory markers (a) IL6, (b) TNF-a, (c) mTOR,
(F1) sacrificed at 8 weeks age (ST group). Data presented is mean ± SEM (n = 8-10, p <
0.05). Common letters indicate no significance.

As illustrated in Fig. 6.13 (a), significantly higher expression of IL6 and TNF-a were
observed in male liver offspring of HF fed father compared to male offspring of LF fed
father. Further, these markers were lower in the liver tissue of male offspring of FO fed father
compared to offspring of HF fed father. No significant difference in the expression of mTOR
in liver of male mice of different groups at 8 weeks was observed. These results highlight the
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role of FO supplementation during paternal obesity in minimizing expression of
proinflammatory biomarkers on offspring during their early life.
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Figure 6.14 Relative expression of fatty acid synthesis markers (a) FASN, (b) SREBP-1c, (c)
mCD36 in liver tissue of male offspring (F1) sacrificed at 8 weeks age (ST group). Data
presented is mean ± SEM (n = 8-10, p < 0.05). Common letters indicate no significance.

Figure 6.14 (a-c) shows the results of the relative expression of fatty acid synthesis markers
FASN, SREBP-1c, and mCD36 in liver of 8 weeks old male offspring of the LF, HF, and FO
fed fathers. From the results on Fig. 6.14 (a, c), no significant differences were observed
among the male offspring of 3 different groups. However, Fig. 6.14 (b) illustrates a
significantly higher expression of SREBP-1c marker in liver of male offspring of HF fed
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father as compared to offspring of LF fed father. Similarly, the expression of SREBP-1c in
male offspring of FO fed father was found to be significantly lower than that offspring of HF
fed father indicating the role of paternal obesity as well as FO supplementation in fatty acid
synthesis genes. From Fig. 6.13 and 6.14, it is inferred that, 8 weeks age is too early for
differences in the expression of several pro-inflammatory and fatty acid markers in mice
offspring. Similar study on 16 weeks mice (LT group) is discussed in section 6.5.2.
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Figure 6.15 Relative expression of fatty acid oxidation markers (a) mFOXO, (b) CPT-1, (c)
PPAR- γ in liver tissue of male offspring (F1) sacrificed at 8 weeks age (ST group). Data
presented is mean ± SEM (n = 8-10, p < 0.05). Common letters indicate no significance.
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Fig. 6.15 (a-c) shows no significant difference in mFOXO, CPT-1, and PPAR- γ levels in the
liver of 8 weeks old offspring of the father fed with HF diet as compared to that of the father
fed with LF diet. Nevertheless, significant higher expression of FOXO in male offspring of
FO fed father was observed as compared to male offspring of HF fed father (see Fig. 6.15
(a)). Similarly, a significant higher expression of CPT-1 in the liver of male offspring of HF
fed father and LF fed father was seen (Fig. 6.15(b)). Combined, effect of paternal obesity on
fatty acid oxidation biomarkers on the male offspring at early stage of life (8 weeks age) is
prominent. Further, FO supplementation during paternal obesity also enhanced the expression
of fatty acid oxidation biomarkers in liver of male offspring at the beginning stage of their
life (Fig. 6.15 (a, b)) which is a significant finding from the mice sacrificed at short term (ST
group).
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Figure 6.16 Relative expression of the gluconeogenesis markers (a) mPDK4, (b) G6P in liver
tissue of male offspring (F1) sacrificed at 8 weeks age (ST group). Data presented is mean ±
SEM (n = 8-10, p < 0.05). Common letters indicate no significance.

Figure 6.16 (a-b) shows that relative expression of mPDK4 and G6P in the male offspring of
LF, HF, and FO fed fathers. FO supplementation on obese fathers during pre-conception
period restored the mPDK4 level on male offspring as shown in Fig. 6.16 (a). mPDK4 which
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mediates lipogenesis and is attributed as a pathogenesis of NASH is found to be lowered due
to FO supplementation on obese fathers which is an interesting finding from the study of liver
of 8 weeks mice.

6.5.2 Liver biomarkers of offspring at 16 weeks (LT)

15

(b)

a
10
b
5

0

b

LF

HF

Male TNF-α
Relative expression

Male IL6
Relative expression

(a)

1.5
a

LF

HF

1.0

0.5

0.0

FO

a

a

FO

(c)

Figure 6.17 Relative expression of pro-inflammatory markers (a) IL6, (b) TNF-a, (c) mTOR
in liver tissue of male offspring (F1) sacrificed at 16 weeks age (LT group). Data presented is
mean ± SEM (n = 8-14, p < 0.05). Common letters indicate no significance.

As shown in Fig. 6.17 (a), a significantly higher expression of IL6 in liver of male offspring
of HF fed father was observed as compared to LF fed father counterparts. Further, expression
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of IL6 in liver of male offspring of FO fed father was significantly lower than offspring of
HF fed father. This illustrates the effect of paternal obesity on the expression of
proinflammatory markers in male offspring as well as the role of FO supplementation during
paternal obesity on minimizing the expression of the same. Furthermore, relative expression
of TNF-α was not different among offspring of LF, HF, and FO fed fathers is shown in Fig.
6.17 (a). However, a significant decrease in expression of mTOR in liver of male offspring
due to supplementation of FO on obese father was observed as seen in Fig. 6.17 (c).

Figure 6.17 in addition to the findings from mice sacrificed at 8 weeks, show the higher risk
of inflammation in male offspring of HF fed father while the metabolic benefits of FO
supplementation during paternal obesity was capable of reducing the risk of such
inflammation as demonstrated through lower expression of biomarkers in male offspring.
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Figure 6.18 Relative expression of fatty acid synthesis markers (a) FASN, (b)SREB-1c, (c)
mCD36 in liver tissue of male offspring (F1) sacrificed at 16 weeks age (LT group). Data
presented is mean ± SEM (n = 8-14, p < 0.05). Common letters indicate no significance.

In addition to the pro-inflammatory biomarkers, we also analyzed the relative expression of
fatty acid synthesis and oxidation markers in liver of male offspring of all 3 groups. FASN
expression in liver of male offspring of HF fed father was comparable to LF fed father as
shown in Fig. 6.18 (a). FO lowered levels of FASN in liver of male offspring of FO fed
compared to offspring of HF fed father. Further, expression of SREBP-1c in liver of male
offspring of HF fed father was significantly higher than that on offspring of LF fed fathers
and the expression was significantly lower due to paternal FO supplementation (see Fig. 6.18
(c)). Similar lowering in the expression of fatty acid synthesis marker mCD36 was also
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observed due to FO supplementation on obese father as shown in Fig. 6.18 (c). Hence, the
expression of FASN, SREBP-1c, and mCD36 show the effect of paternal obesity as well as
the role of FO supplementation for fathers on the fatty acid synthesis mechanism on male
offspring. This finding of the relative expression of biomarkers including CD36 which is
known to be associated strongly with and NAFLD [96] which further sheds light on the
effectiveness and significance of FO supplementation for obese fathers to reduce the risk of
NAFLD.
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Figure 6.19 Relative expression of fatty acid oxidation markers (a) mFOXO, (b) CPT-1, (c)
PPAR- γ in liver tissue of male offspring (F1) sacrificed at 16 weeks age (LT group). Data
presented is mean ± SEM (n = 8-14, p < 0.05). Common letters indicate no significance.
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As shown if Fig. 6.19 (a-c), there was no significant difference observed in terms of the
expression of mFOXO, CPT-1, and PPAR- γ among male offspring of LF, HF, and FO fed
father. Although significant difference in the expression of fatty acid oxidation markers
FOXO and CPT-1 among the male offspring of LF, HF, and FO fed fathers was observed in
the case of mice sacrificed at 8 weeks of age (ST group) (see Fig. 6.15), such significant
difference was diminished in the latter stage of life. This shows the need of further study of
FA oxidative markers in the liver of mice during paternal obesity and FO supplementation.
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Figure 6.20 Relative expression of gluconeogenesis markers (a) mPDK4, (b) G6P in liver
tissue of male offspring (F1) sacrificed at 16 weeks age (LT group). Data presented is mean
± SEM (n = 8-14, p < 0.05). Common letters indicate no significance.

Similar to the analysis of mice sacrificed at 8 weeks, the expression of mPDK4 and G6P was
performed at 16 weeks as well as shown in Fig. 6.20. Due to supplementation of FO to obese
father during pre-conception, the expression of mPDK4 was lowered in male offspring as
shown in Fig. 6.20.
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CHAPTER 7. CONCLUSION AND FUTURE WORK

7.1 Summary of Findings

In summary, the study presents the effects of fish oil supplementation on paternal obesity and
its impacts on offspring metabolic and cardiovascular health. Our results showed that
offspring of HF fed fathers had higher birth weight compared to offspring of LF fed fathers
directly illustrating the programming of paternal obesity on offspring. This result excludes
the effects of maternal obesity as dams were fed a LF diet and were lean during mating,
pregnancy until weaning. Body weight was reduced in offspring of FO fed fathers although
the FO fathers were in average equally obese as HF fathers. Specifically, male offspring of
FO fed fathers had significantly lower body weight than obese fathers without FO
supplementation counterparts (i.e., HF group) through the latter stage of their life 8 – 16
weeks. This clearly demonstrates the effectiveness of FO supplementation during paternal
obesity on lowering the average body weight and reducing the risk of obesity on offspring at
least in males. Similar to our study, other studies showed higher body weight of offspring
due to higher sugar consumption by the father in Drosophila [74] or high fat diet induced
paternal obesity in mice [69] [79] [78]. Nevertheless, studies providing effective intervention
to reduce the effect of paternal obesity on offspring body weight are scarce, and usually focus
only on intervention through physical exercise [79] rather than dietary supplementation.
Current work provides the evidence of FO supplementation on controlling childhood obesity
as well as degrading the programming effect of father’s obesity on child health and
development.
Moreover, glucose and insulin tolerance tests in offspring showed severe impairment in
offspring of HF fed fathers compared to offspring of LF fed father. FO supplementation
during paternal obesity could stabilize the glucose and insulin tolerance in offspring
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compared to offspring of obese fathers. Such impaired glucose and insulin sensitivity are risk
factors for development of type-2 diabetes, cardio-vascular diseases [6] which account for a
leading cause of mortality and premature disability [6] due to non-communicable diseases
world-wide. In this regard, our study on FO supplementation in father infers FO as a key diet
to obese father during pre-conception period.
As compared to the offspring of healthy fathers, offspring of obese fathers were previously
found to have elevated levels of serum alanine aminotransferanse (ALT), a liver enzyme [73]
leading to liver disease in offspring. To comprehend the development of fatty liver leading to
NAFLD, I analyzed the liver histology in offspring. The histology revealed a higher fat
deposition in offspring liver of HF fed fathers compared to the offspring of the LF fed
fathers. Programming due to paternal obesity on offspring along with impaired glucose and
insulin sensitivity leads to such fat deposition. Such fat deposition was found to be lower in
liver of offspring of FO fed fathers inferring another beneficial effect of FO supplementation
during paternal obesity.
Paternal obesity has adverse effects on offspring health and development carried on through
trans-generational programming [64]. Pre-conceptional risk factors of father including
obesity, diabetes mellitus, nutritional or dietary habits, lifestyles, substance abuses, etc.
mediates through impaired molecular profile of spermatozoa [68] and alteration in sperm
epigenetics for programming offspring phenotypes [65]. Thus, to comprehend the
physiological mechanism and genes involved in impaired health of offspring of obese father,
I analyzed the expression of pro-inflammatory and fatty acid markers in liver of male
offspring by sacrificing at two different time points at 8 and 16 weeks called (ST) and longterm (LT) respectively. Significantly higher expression of pro-inflammatory markers IL6 (at
both ST and LT), TNF-α (at ST), mPDK4 (at ST), mTOR (at LT), and mCD37 (at LT), in the
liver of the male offspring of HF fed father as compared to the male offspring of LF fed
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fathers were observed. Also, significantly lowered expression of IL6 (at both ST and LT),
TNF-α (at ST), mPDK4 (at both ST and LT), mTOR (at LT), and mCD36 (at LT) in the male
offspring of FO supplemented father was obtained as compared to the male offspring of HF
fed father. Similarly, significantly higher expression of fatty acid synthesis marker FASN (in
LT), SREBP-1c (in both ST and LT) was observed in liver of male offspring of HF fed father
as compared to the male offspring of LF fed father. Due to FO supplementation during
paternal obesity, the expression of FASN (at LT) SREBP-1c (at both ST and LT) in liver of
male offspring got significantly reduced as compared to that of male offspring of obese father
without FO supplementation. Finally, the relative expression of fatty acid oxidation markers
FOXO and CPT-1 in liver of male offspring was found to be lowered due to FO
supplementation on father as compared to the obese father without FO supplementation.
FO supplementation during paternal obesity was effective in down-regulating the expression
of pro-inflammatory and fatty acid synthesis markers as well as enhancing certain oxidation
markers in liver of offspring as compared to the liver of offspring of obese fathers.
7.2 Implication
Given the rise of obesity and associated cardiovascular dysfunctions in human population
worldwide, it is crucial to comprehend the mechanistic study of obesity and transgenerational
effects. In this scenario, the current work serves a purpose of additional resource on lesser
discussed topic in literature i.e., paternal obesity. Here, we demonstrate the benefits of preconception fish oil supplementation in obese father on offspring health and development.
Furthermore, the focus of future study should lie on the development of effective intervention
technique to ameliorate the negative outcomes of father’s obesity on children along with the
detail comprehension of the metabolic pathway. Evidence [94, 97, 98] shows the genderbased differentiation of the effect of parent’s obesity on male and female offspring which also
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needs to be understood better to find the cure of this chronic disease. Additionally, the
relative effectiveness of the father’s weight loss, physical exercise, and dietary
supplementation on reducing the risk of mal-programming and metabolic alternation on
offspring is also equally important to understand. With the positive association of weight loss
with lower inflammation, cardiovascular risk factors [99-101], additional probe on weight
loss of father needs to be done. The current study shows improvement in offspring’s
metabolic health through supplementing FO in father’s diet but the FO supplementation itself
doesn’t cause reduced body weight on father. The FO supplemented fathers were equally
obese as HF fed fathers so future work also should focus on weight loss for the fathers that
can further provide newer insights towards prevention of obesity.
7.3 Future Work
In the future, I would like to study the implication of paternal obesity and FO
supplementation on both male and female offspring (F1) as well as investigate the transgenerational effect and obesity programming till F2 generation. Literature suggests that
paternal obesity in mice can program the metabolic disturbance to F2 generation [69] as well
which suggests conducting large-scale studies in future. Similarly, the study of gene
expression of inflammatory and fatty acid biomarkers on offspring immediately after
weaning (i.e., at 4 weeks of age) is absent in the present work. This should be done to better
understand paternal FO supplementation and offspring metabolism during early stage of life.
In the current study, I focused on liver weight, liver histology and gene expression of isolated
RNA from liver only. However, to further dig into the risk of liver diseases due to mal
programming in paternal obesity, additional techniques of advanced mass spectrometry,
magnetic resonance technology, computed tomography, etc. can be performed with the
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existing (frozen) liver tissue in future. Such study can provide newer insights to the risk of
liver diseases due to paternal obesity.
Further, I want to study in depth the biomarkers associated with fatty acid oxidation on
offspring liver. Due to limitation of time and with an aim of optimizing resources, detailed
study of fatty acid oxidation biomarkers is yet pending. This can be performed to have better
understanding of metabolic impairment on offspring due to paternal obesity. Furthermore, in
the future, I would like to study the expression of pro-inflammatory and fatty acid biomarkers
on the adipose tissue of offspring as well.
Finally, in the present study, the offspring of all three groups of fathers were fed with control
diet (LF) only. Here, a similar study can be conducted with offspring being fed with different
combination of diets e.g., the offspring of HF fed father can be continued to fed HF after
weaning to see the effect of double-hit of high-fat diet or the offspring of FO fed father can
also be fed with FO diet after weaning to see double-hit of FO supplementation, etc. With
such combinations, further idea on continued expression of gene and programming in
offspring health and risk to metabolic diseases can be studied.
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Appendix

A1 Protocols for RNA Isolation

Materials:
1. Dry Ice (Room 0-005)
2. Ice box with ice
3. Single edge Blade (PAL)
4. TissueLyser Shaker
5. Centrifuge (4°C and normal)
6. Eppendorf tube (2 ml, 1.5ml) four sets (precipitation, aqueous transfer, filtration and
final storage(1.5ml)) for each sample
7. SS beads (ø 0.48 mm)
8. Trizol lysis reagent
9. RNA isolation kit box (Zymo Research)
10. Nuclease-free water
11. Micropipette tips of size 20μl, 200μl and 1000 μl
12. Micropipette set of various size
RNA isolation.
1.

Make sure to cut the tissue on Dry Ice.

2. Label all the tubes with sharpie according to the cohort the sample was collected
from. (Top of the tube)
3. Cut a small piece of tissue on dry ice and add into the corresponding 2 ml tube.
4. Add one Stainless Steel bead into the tube.
5. Add 500- 700 Ul of Trizol (yellow cabinet) lysis reagent to tube.
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6. Place tubes into TissueLyser at 50 oscillations for 5 minutes to disrupt cells. Make
sure balance the tissue lyzer (even number of samples on both sides of the holder).
7. Transfer to a new labeled tube.
8. Add 300 µl of chloroform to each tube. (chloroform fall quickly from tips! Transfer it
mouth to mouth.)
9. Shake tubes vigorously by hand for 15 seconds & keep in room temperature for 2
minutes.
10. Make sure the centrifuge is cold. Press the required temperature and press fast temp.
11. Centrifuge the samples at 4°C, 12,000 g for 15 min.
12. 600 µl of the supernatant (layer should have no precipitate) was transferred to a new
2ml tube. Don’t touch the pink layer (important). If the separation is not good go
back to step 8 and do the chloroform purification again, reduce the time to 5 min.
13. Add 1 volume (same volume of collected upper aqueous from step 12), about 300 –
600 µl ethanol (95-100%) and vortex for 5 seconds.
14. Transfer the mixture to a ZYmo-Spin IIICG column (Green) in a collection tube and
centrifuge at room temperature for 1 minute. Discard the flow-through.
15. Add 400 µl RNA Wash Buffer to the column and centrifuge (16,000rpm, 30sec)
16. Take 5 µl X n (n = number of samples) DNase I (DNase is in -20oC refrigerator.) +
75 µl (75 µl in protocol) DNA Digestion buffer. Mix by inversion in an RNase free
tube.
17. Add 80 µl of the mix directly to the samples
a. For example: If you’re doing 4 samples, n = 5 (n +1), so 5 x 5 = 25 of DNase
+ 75 x 5 = 325 µl of DNA digestion buffer. Take 80 µl of this mixture and add

73

to each of the 4 samples.
b. If no DNase is available, you can make it by adding 275 H2O to the DNase
concentrate tubes found in yellow box. Take 25 µl and separate this mixture
into various tubes.
c. 10 µl of DNase = 150 µl of buffer, so for 1 sample: 5µl = 75 µl of buffer.
18. Incubate at room temperature for 15 minutes
19. Add 400 µl RNA Prep Buffer to the column and centrifuge (16,000rpm, 30sec).
Discard the flow-through
20. Add 700 µl RNA Wash Buffer to the column and centrifuge (16,000rpm, 30 sec).
Discard the flow-through
21. Add 400 µl RNA Wash Buffer to the column and centrifuge (16,000rpm, 2 min).
Discard the flow-through.
22. Centrifuge the column again for 1min at max speed to ensure complete removal of
buffer
23. To elute RNA, add 50 µl DNase/RNase-Free Water directly to the column matrix.
Transfer the column on a properly marked RNase free 1.5ml Eppendorf tube and
centrifuge for 1 minute. Use ice until refrigeration of the sample. Make sure to add to
the disc in column.
24. Keep all the samples in -80°C until put onto nanodrop for RNA concentration
measurements.
25. To use nanodrop:
a. Turn on and make sure arm is down.
b. Select RNA.
c. Blank with RNA free water.
d. Load samples onto pedestal (hit measure) and wipe down after each sample.
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e. Write down data when complete.

A2 Protocols for Preparing cDNA using High-Capacity Kit from Applied biosystems

1) Thaw all RNA samples on ice until all the ice is melted away.
2) Measure all RNA again so that there is less variability.
3) Meanwhile, use the cDNA kit from -20 and take all the tubes and leave them on ice to
thaw.
4) Calculate the total volume of RNA and RNase free water: Using excel, divide
1000mg/RNA concentration(ug/uL) to calculate the amount of RNA you will need
per sample. Subtract that number from 14.2 to calculate the amount of RNase free
water per sample.(we do this since the total volume is 20 ul per reaction)
5) Add the required amount of water into the 0.2 ml strip tube.
6) Then add the RNA in a same tube.
7) In a separate 1.5mL tube, mix together the following:
10x RT Buffer

2.0uL x Number of samples + 4 = 70

25x DNTP Mix

0.8uL x Number of samples + 4= 28

10x random Primer

2.0uL x Number of samples + 4 = 70

enzyme

1.0 ul X number of samples + 4 = 35

Total solution

5.8uL

8) Add 5.8uL of the solution to each sample.
9) Mix gently and spin for 30 seconds
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10) Mix gently and spin for another 30 seconds
11) Take the tubes to the PCR machine for cDNA and run the protocol, “PCR” (25 C for
10 minutes, 37C for 120 minutes, 85C for 5 minutes, and 4 for infinite hold.)
12) Turn off the machine by cancelling run and hit ‘OK’
13) Add 80 ul of water to the cDNA tubes.
14) Now take 1.5 ml tubes, write the full name of the sample, add 380 ul of water into all
the tubes and then add 95 ul of the sample. This is 1: 4 dilution.
15) Store at -20C

A3 Protocols for Gene Expression

Things Needed:
1) Primers:
Master stock of primer: Is located in -20 in a red sigma box. Also, stored in -20.
Working stock: Find it in the box named working stock. If you don’t find it, use the
master stock. It’s a 1:4 dilution, So take 100 ul of the primer from main stock and add
400 ul of water. Label it forward and reverse primers respectively.
2) Master mix: in 4 degrees door. If not, check -20 for a new vial.
3) Water: On the bench
4) PCR PLATES: In the shelf on the opposite side of the bench.
Procedure
1) Thaw cDNA samples and primers.
2) For each plate:
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R primer

1 ul x number of wells

(working stock)

F primer

1 ul X number of wells

(working stock)

Master Mix

10 ul X number of wells

Water

3 ul X number of wells

Based on the number of wells used, make master mix for 10 extra wells.
For example: if you are doing the whole plate, calculate for 110 wells.
F primer: 1 ul X 110 = 110 ul
R PRIMER: 1 UL x 110: 110 ul
Master mix: 10 X 110= 1100ul (set pipette to 550 ul and add twice).
Water: 3 X 110 ul = 330 ul.
Add all of the above to a 2mL tube.
Important: Vortex all tubes before using them
Plate is found in the drawer labeled PCR or in the shelf on the opposite side.
Water & primers were added to a 2 ml Eppendorf tube (volumes as given above)
•

SYBR master mix was then added to the water + primer mixture and vortexed.

•

5 µl of cDNA from each sample was added to the PCR plate in triplicates
(VORTEX).

•

15 µl of the above mixture was added to each well in the plate and vortex between
each row.

•

Cover the plate , vortexed and spin in the centrifuge (to the right of the qPCR
machine).

•

Gene expression was run in the Quantstudio3 PCR machine

•

Please the eject button on the machine screen to put the plate in.
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•

Open the quant studio software in the desktop, open new experiment or template, and
then adjust the plate settings and please run. Make sure to save the file.

•

Results were uploaded to Thermofisher cloud.
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